See every side of every news story
Published loading...Updated

FDA Approves TNKase for Acute Ischemic Stroke

  • The U.S. Food and Drug Administration has approved TNKase for treating acute ischemic stroke in adults.
  • TNKase is given as a single five-second intravenous bolus, which is faster than the current standard treatment, Activase .
  • Genentech's new 25-mg vial of TNKase will be available in the coming months, following the approval.
  • Approval was based on a study showing TNKase's efficacy and safety were comparable to Activase.
Insights by Ground AI
Does this summary seem wrong?

31 Articles

All
Left
4
Center
6
Right
2
WFMZWFMZ
+27 Reposted by 27 other sources
Center

FDA Approves TNKase for Acute Ischemic Stroke

THURSDAY, March 6, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved TNKase (tenecteplase), a thrombolytic or clot-dissolving agent, for the treatment of acute ischemic stroke in adults.

·Pennsylvania, United States
Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 50% of the sources are Center
50% Center
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

KULR-TV broke the news in Billings, United States on Thursday, March 6, 2025.
Sources are mostly out of (0)

Similar News Topics

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.